Presentation is loading. Please wait.

Presentation is loading. Please wait.

B. Soubeyrand - VHPB October 2001 Malte 1 HEXAVAC ® A new liquid DTacP-IPV-Hib-HB hexavalent vaccine Overview of its clinical profile Benoît Soubeyrand.

Published byHillary Floyd Modified over 8 years ago

Similar presentations

Presentation on theme: "B. Soubeyrand - VHPB October 2001 Malte 1 HEXAVAC ® A new liquid DTacP-IPV-Hib-HB hexavalent vaccine Overview of its clinical profile Benoît Soubeyrand."— Presentation transcript:

1 B. Soubeyrand - VHPB October 2001 Malte 1 HEXAVAC ® A new liquid DTacP-IPV-Hib-HB hexavalent vaccine Overview of its clinical profile Benoît Soubeyrand M.D. (Courtesy L. Hessel)

2 B. Soubeyrand - VHPB October 2001 Malte 2 What is Hexavac ® ? Clinical development plan Safety profile Immunogenicity Conclusions HEXAVAC ® : A NEW LIQUID DTaP-IPV-HIB-HB HEXAVALENT COMBINATION VACCINE.

3 B. Soubeyrand - VHPB October 2001 Malte 3  purified diphtheria toxoid,20 IU (30 Lf)  purified tetanus toxoid, 40 IU (10 Lf)  adsorbed purified pertussis toxoid, 25  g  adsorbed purified FHA, 25  g  Polio type 1 (Mahoney strain), 40 D units  Polio type 2 (MEF 1 strain), 8 D units  Polio type 3 (Saukett strain), 32 D units  PRP-T, 12  g (PRP)  adsorbed, purified HBsAg, 5  g WHAT IS HEXAVAC ® (1): Composition and Presentation A unique ready to use, preservative-free, liquid formulation, combining all 6 antigens in 0.5 ml

4 B. Soubeyrand - VHPB October 2001 Malte 4 Start of the projectFeb. 94 1st clinical lot availableJan. 95 1st inclusion phase 1Feb. 95 1st inclusion phase 2May 95 1st consistency batch (development scale) July 95 1st inclusion phase 3June 96 1st consistency batch (industrial scale)Dec. 98 1st industrial lotApril 99 EMEA submissionJuly 99 CPMP positive opinionJune 00 Market autorisationOct. 00 Launch in GermanyOct. 00 WHAT IS HEXAVAC ® (2): Critical timelines i.e.- 5 years and 5 months: time to develop - 6 years and 8 months: time to register / market

5 B. Soubeyrand - VHPB October 2001 Malte 5 200 different experimental formulations prepared, varying :  pH  ionic strength of different buffers (C0 3 2-, P0 4 3- )  batches of antigens  batches of adjuvant from different manufacturers  concentration of antigens  order of addition of antigens, adjuvant, buffer as well as conditions of blending 50 different hexavalent formulations physico-chemically and immunologically tested 7 optimized formulations extensively tested at 4°C, RT, 37°C 2 semi-final formulations tested, over time, at + 4°C 1 final formulation for clinical development and industrial production WHAT IS HEXAVAC ® (3): Formulation Process

6 B. Soubeyrand - VHPB October 2001 Malte 6 Goals of clinical development :  To show that the hexavalent combination vaccine is safe and induces protective immune responses equivalent (non-inferior) to previously licensed combination vaccines PENTAVAC™ and RECOMBIVAX ®  To support clinically the consistency of manufacture by comparing the immunogenicity of three consecutively batches  To support the use of the vaccine with various vaccination regimens : 2, 3, 4 / 12-18 months or 2, 4, 6 / 12-18 months ; 3, 5 / 12 months HEXAVAC  : Clinical development Plan (1)

7 B. Soubeyrand - VHPB October 2001 Malte 7 Pivotal study – France (A) HEXAVAC ® : n=423 PENTAVAC™ + RECOMBIVAX ® n=425 2, 4, 6/12-18 months Schedule study – France (D) HEXAVAC ® 2, 3, 4/15-17 months : n=258 Versus 2, 4, 6/15-17 months : n=258 Consistency lot study – Chile (B) HEXAVAC ® 3 lots 2, 4, 6 months : n=311 to 359 per group Large scale safety – Germany (C) HEXAVAC ® 2, 4, 6/12-14 months : n=1,783 Safety in toddler : France HEXAVAC ® : n=30 Versus DTaP-IPV-Hib/HB : n=28 14-18 months Schedule study – Sweden (E) HEXAVAC ® : n=180 3, 5, 12 months PHASE I StudyPHASE II Study PHASE III Studies Choice of formulation : France HEXAVAC ® : n=157 Versus DTaP-IPV-Hib/HB : n=155 2, 3, 4/12-14 months HEXAVAC  : Clinical development Plan (2)

8 B. Soubeyrand - VHPB October 2001 Malte 8 PHASE III studies : booster vaccination. Safety of HEXAVAC ® in children primed with DTwP-IPV-Hib (PENTACOQ ® ), France (F) n = 1,304 2, 3, 4/16-20 months Safety & Immunogenicity of HEXAVAC ® in children primed with DTaP-IPV-Hib (PENTAVAC TM ) + RECOMBIVAX ®, Turkey (H) n = 129 2, 3, 4/14-18 months Safety & Immunogenicity of HEXAVAC ® in children primed with DTwP-IPV-Hib (PENTACOQ ® ) + RECOMBIVAX ®, France (G) n = 313 2, 3, 4/14-20 months HEXAVAC  : Clinical development Plan (3)

9 B. Soubeyrand - VHPB October 2001 Malte 9 Database submitted in the application file to CPMP  11 507 doses of vaccines administered to 3 905 infants in primary series.  4 437 booster doses given to toddlers primed with either whole- cell or acellular Pertussis combination vaccines : - Pentacoq™ ( DTwP-IPV//PRP-T) - Pentavac™ ( DTaP-IPV//PRP-T) E uropean license received on October 24 th 2000 HEXAVAC  : Clinical development Plan (4)

10 B. Soubeyrand - VHPB October 2001 Malte 10 HEXAVAC ® : Safety profile (1) In all studies, evaluation of safety included: 1. Immediate reactions within the first 30 minutes after each dose 2. Local reactions and systemic events from 30 minutes to 72 hours following each dose 3. Any adverse event that resulted in a visit to a physician 4 and 30 days after each injection 4. Any serious adverse event (SAE) occurring throughout the trial.

11 B. Soubeyrand - VHPB October 2001 Malte 11 Local reactions (%) following primary series in infants receiving HEXAVAC ® (N = 423) or PENTAVAC TM + RECOMBIVAX ® (N = 425 ) % of Infants 0 5 10 15 20 25 Any reaction Swelling  2 cmRedness  2cm 20.3 15.8 3.3 14.5 13.8 3.8 12.1 6.8 1.5 HEXAVAC ® PENTAVAC TM RECOMBIVAX ® HEXAVAC ® : Safety profile (2)

12 B. Soubeyrand - VHPB October 2001 Malte 12 Local reactions (%) within 3 days of a booster dose (12-18 months) of HEXAVAC ® (n=400) or PENTAVAC TM + RECOMBIVAX ® (n=402) % of infants 0 5 10 15 20 25 30 35 Any reaction Redness  2cm Swelling  2cm 26.9 28.7 10.2 19.9 24.4 8.0 20.9 20.7 8.0 HEXAVAC ® PENTAVAC TM RECOMBIVAX ® HEXAVAC ® : Safety profile (2)

13 B. Soubeyrand - VHPB October 2001 Malte 13 0 10 20 30 40 50 60 Any eventFever  38°C drowsiness Irritability % of infants 45.7 42.2 14.7 14.5 11.3 26.9 23.7 9.9 Mallet E. et al. Pediatr Infect Dis J, 2000; 19:1119-27 HEXAVAC ® : Safety profile (3) Systemic reactions (%) following primary series in infants receiving HEXAVAC ® (N = 402-423) or PENTAVAC TM + RECOMBIVAX ® (N = 425) HEXAVAC ® PENTAVAC TM + RECOMBIVAX ®

14 B. Soubeyrand - VHPB October 2001 Malte 14 Systemic reactions (%) within 3 days of a booster dose (12-18 months) of HEXAVAC ® (n=400) or PENTAVAC TM + RECOMBIVAX ® (n=402) % of infants 0 10 20 30 40 50 Systemic adverse events 40.5 47.6 29.4 32.4 3.7 7.0 18.2 20.0 HEXAVAC ® PENTAVAC TM + RECOMBIVAX ® HEXAVAC ® : Safety profile (4) Any event Fever  38°C DrowsinessIrritability Mallet E. et al.

15 B. Soubeyrand - VHPB October 2001 Malte 15 primary series in Local and systemic reactions (%) within 3 days following primary series in infants and booster in children primed with Hexavac ® HEXAVAC ® : Safety profile (5), summary Number of infants Dose # 1 3897 Dose # 2 3826 Dose # 3 3784 All doses 11507 Booster 2688 Local reactions Any local reaction14.117.919.617.221.3 Redness  2 cm 6.810.012.2 9.417.4 Induration and/or swelling  2 cm 10.212.613.412.015.6 Systemic adverse events Irritability and/or unusual crying25.725.322.024.415.6 Drowsiness15.2 8.8 6.310.1 5.7 Fever  38°C 38-38.9°C9.0618.0 15.024.9 39-39.9°C0.44 1.6 2.7 1.6 3.6  40°C 0.030.130.160.100.74

16 B. Soubeyrand - VHPB October 2001 Malte 16 ANTIGEN CRITERIA FOR SEROCONVERSION OR SEROPROTECTION PRP antibody titre  0.15 µgml HBs antibody titre  10 mlU/ml Diphtheria antibody titre  0.01 lU/ml * Tetanus antibody titre  0.01 lU/ml PT four-fold rise of pre-immunisation titre* FHA four-fold rise of pre-immunisation titre* Poliovirus type 1, 2, 3 antibody titre  5 (reciprocal dilution for each serotype) * Response measured by EIA HEXAVAC ® : Immunogenicity (1)

17 B. Soubeyrand - VHPB October 2001 Malte 17 Seroprotective titres Seroprotection rate (%) HEXAVAC ® PENTAVAC TM +RECOMBIVAX ® (n = 305-331) (n = 301-332) 0 20 40 60 80 100 HBsAgPRPPTFHATetanusDiphtheriaPoliovirus  0.15 µg/ml  10 mIU/ml  4- fold increase  4- fold increase  0.01 IU/ml  0.01 IU/ml 55 (1/dil) 96.6 100 93.7 99.7 91.8 93.7 90.5 88.6 100 99.7 100 Comparison of Seroprotection / Seroconversion rates between Hexavac ® and Pentavac TM + Recombivax ® 1 month after the primary series (2, 4, 6 months) Mallet E. et al. Pediatr Infect Dis J 2000; 19 : 1119-27 HEXAVAC ® : Immunogenicity (2)

18 B. Soubeyrand - VHPB October 2001 Malte 18 PT FHA D T Polio 1 Polio 2 Polio 3 Post-dose 3, pre- and post-booster antibody results (GMTs) Mallet E. et al. Pediatr Infect Dis J 2000; 19 : 1119-27 HEXAVAC ® : Immunogenicity (3) Pentavac TM + Recombivax ® Hexavac ®

19 B. Soubeyrand - VHPB October 2001 Malte 19 Post- dose 3, pre-booster and post-booster anti-HBs antibody responses: GMTs (% seroprotection rates) 434 (96.6) 10 100 1000 10000 HBs 3026 (100) 932 (96.6) 983 (100) 47.3 (81.7) 332 (98.4) Mallet E. et al. Pediatr Infect Dis J 2000; 19 : 1119-27 HEXAVAC ® : Immunogenicity (4) HBs antibody (mIU/ml) Pentavac TM + Recombivax ® Hexavac ® post dose 3pre-boosterpost-booster

20 B. Soubeyrand - VHPB October 2001 Malte 20 anti HBs (mIU / ml) after primo-immunisation with various vaccines HEXAVAC ® : Protection against Hepatitis B VaccineAGE (m)NGMT %  10 HEXAVAC ® 2, 4, 630043496.6 PENTAVAC ® + RECOMBIVAX ® 2, 4, 6300983100 RECOMBIVAX ® 0, 1, 6100931100 PEDVAX ® + RECOMBIVAX ® 2, 418025698.4 PROCOMVAX ® 2, 455011492.1

21 B. Soubeyrand - VHPB October 2001 Malte 21 Post dose 3, pre-booster and post-booster anti-PRP antibody responses: GMTs (% seroprotection rates) 3.69 (99.7) 2.06 (93.7) Pentavac TM + Recombivax ® Hexavac ® 23.0 (100) 16.7 (100) 0,01 0,1 1 10 100 post dose 3pre-boosterpost-booster Hib 0.6 (91.4) 0.4 (77.5) Mallet E. et al. Pediatr Infect Dis J 2000; 19 : 1119-27 Anti-PRP antibody (µg/ml) HEXAVAC ® : Immunogenicity (5)

22 B. Soubeyrand - VHPB October 2001 Malte 22 GMC after primary immunisation in the first 6 months of life HEXAVAC ® : Protection against Hib 100 10 1 0.1 Anti-PRP titres (µg/ml) Pentavac Ⓡ Hexavac Ⓡ Eskola J. Lancet 1999; 354 : 2063 PRP-T separate PRP-T mixed PRP-DPRP- OMP PRP-THbOC

23 B. Soubeyrand - VHPB October 2001 Malte 23 Seroprotection / seroconversion rates one month following the administration of HEXAVAC® at 2, 4, 6, or 2, 3, 4, months of age Seroprotective titres  10 mIU/ml  4- fold increase  0.01 IU/ml  0.01 IU/ml µg/ml  0.15  5 (1/dil)  4- fold increase HEXAVAC ® : Immunogenicity (6) Camier P. et al. ESPID 2000

24 B. Soubeyrand - VHPB October 2001 Malte 24 Seroprotection / seroconversion rates one month following the booster dose of HEXAVAC® given at 2, 3, 4 / 15-17, or 2, 4, 6 / 15-17 or 3, 5 / 12 months of age Camier P. et al : ESPID 2000; Flodmark CE et al : PIDS 2001 HEXAVAC ® : Immunogenicity (7) Seroprotective titres  10 mIU/ml  0.10 IU/ml  0.10 IU/ml  1.0 µg/ml  5 (1/dil)  4- fold increase  4- fold increase

25 B. Soubeyrand - VHPB October 2001 Malte 25 CONCLUSIONS Hexavac ®, the liquid combined hexavalent vaccine : is well tolerated provides protection and seroconversion in the range of other licensed vaccines containing aP immune responses to PRP and HBs are in the range of those reported with vaccines proven to be efficacious confers excellent priming for all antigens as evidenced by strong booster responses

26 B. Soubeyrand - VHPB October 2001 Malte 26 Aventis PasteurMerck & Co.Aventis Pasteur MSD A. Hoffenbach E. Pines P. Fabre E. Vidor H. Salomon M. Dupuy C. Blondeau P. Mendelman J. Boslego F. Schödel H. Matthews T. Staub G. Chryssomalis M. Garnier L. Hessel Investigators : E. Mallet, J. Lang, P. Camier, P. Reinert, F. Undreiner, F. Roussel, R. Lagos, M. Levine B. Belohradsky, J. Liese, S. Stojanov, G. Kanra, P. Carriere, M. Girard, M. Muller and all participating pediatricians Hexavac project team And all participating babies and parents HEXAVAC ® : Clinical development team

Download ppt "B. Soubeyrand - VHPB October 2001 Malte 1 HEXAVAC ® A new liquid DTacP-IPV-Hib-HB hexavalent vaccine Overview of its clinical profile Benoît Soubeyrand."

Similar presentations

WHO/V&B/AVI Choosing the Right Vaccine A brief presentation on hepatitis B & Haemophilus influenzae type b infections and choosing the right vaccines to.

WHO/V&B/AVI Choosing the Right Vaccine A brief presentation on hepatitis B & Haemophilus influenzae type b infections and choosing the right vaccines to.
Combined Veccination Against Hepatitis A & Hepatitis B The Rationale For a combine Hepatitis A/B Vaccine. Twinrix Twinrix is a vaccine which combines.

Combined Veccination Against Hepatitis A & Hepatitis B The Rationale For a combine Hepatitis A/B Vaccine. Twinrix Twinrix is a vaccine which combines.
Immunisation. 1796 If you understand basic immunology you can explain... How vaccines work and why vaccine failures occur Adverse events and their.

Immunisation If you understand basic immunology you can explain... How vaccines work and why vaccine failures occur Adverse events and their.
Feb 2011 Dr Guada Lopez Marti Pediatric Infectious Diseases Marshall University.

Feb 2011 Dr Guada Lopez Marti Pediatric Infectious Diseases Marshall University.
Prevalence of HBV* by Region

Prevalence of HBV* by Region
Combination Vaccines Partners in Prevention Coalition of Dodge County and City of Watertown Spring 2014 Betsy Peterson, MD.

Combination Vaccines Partners in Prevention Coalition of Dodge County and City of Watertown Spring 2014 Betsy Peterson, MD.
Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.
Use of Infanrix®-IPV+Hib in the infant primary immunisation schedule Information for healthcare practitioners.

Use of Infanrix®-IPV+Hib in the infant primary immunisation schedule Information for healthcare practitioners.
A 23 year old business woman got two shots of hepatitis B 1 month apart 2 years ago. Today she is at your practice for ending the schedule. What should.

A 23 year old business woman got two shots of hepatitis B 1 month apart 2 years ago. Today she is at your practice for ending the schedule. What should.
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Boostrix TM ) Ann T. Schwartz, MD CBER, FDA Vaccines and Related Biological.

Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Boostrix TM ) Ann T. Schwartz, MD CBER, FDA Vaccines and Related Biological.
Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.
Hib Vaccines: What is new ?? A Review

Hib Vaccines: What is new ?? A Review
Haemophilus influenzae type B and Hib Vaccine Dr Seyed Mohsen Zahraei Center for Communicable Disease Control.

Haemophilus influenzae type B and Hib Vaccine Dr Seyed Mohsen Zahraei Center for Communicable Disease Control.
Rashmi Ranjan Das, Inusha Panigrahi, Sushree Samiksha Naik PLOS ONE- September 2014 Volume 9. Issue 9 Prepared by: Maha al Arrayed Supervised by: Dr Salwa.

Rashmi Ranjan Das, Inusha Panigrahi, Sushree Samiksha Naik PLOS ONE- September 2014 Volume 9. Issue 9 Prepared by: Maha al Arrayed Supervised by: Dr Salwa.
Pertussis and Pertussis Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control.

Pertussis and Pertussis Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control.
Immunoprophylaxis (prophylactic immunization). Immunoprophylaxis Types of immunization Immunoglobulins and vaccines Strategies in vaccine preparation.

Immunoprophylaxis (prophylactic immunization). Immunoprophylaxis Types of immunization Immunoglobulins and vaccines Strategies in vaccine preparation.
The Prime Minister of Pakistan launching NIDs. Oral Polio Vaccine (OPV) Protect against poliomyelitis 4 doses (1st dose soon after birth and then at 6,

The Prime Minister of Pakistan launching NIDs. Oral Polio Vaccine (OPV) Protect against poliomyelitis 4 doses (1st dose soon after birth and then at 6,
19th VHPB meeting on combined hepatitis B vaccines, Malta 22- 23.10.01, Dr. M. Pfleiderer, PEI 1 European Regulatory Authorities´ Perspective and View.

19th VHPB meeting on "combined hepatitis B vaccines", Malta , Dr. M. Pfleiderer, PEI 1 European Regulatory Authorities´ Perspective and View.
National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.
Pertussis and Pertussis Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control.

Pertussis and Pertussis Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control.

Similar presentations

Ads by Google